Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease

This study has been completed.

First Received: December 6, 2000 Last Updated: January 21, 2009 History of Changes

Sponsor:	National Center for Research Resources (NCRR)
Collaborator:	Children's Hospital Medical Center, Cincinnati
Information provided by:	National Center for Research Resources (NCRR)
ClinicalTrials.gov Identifier:	NCT00007033

Purpose

OBJECTIVES:

I. Determine the role of magnesium deficiency in the pathogenesis of decreased serum vitamin D and reduced bone density in children with chronic cholestatic liver disease.

Condition	Intervention
Alagille Syndrome Cholestasis Biliary Atresia	Drug: magnesium gluconate Drug: magnesium sulfate

Study Type:	Interventional
Study Design:	Treatment

Resource links provided by NLM:

Genetics Home Reference related topics: Alagille syndrome

MedlinePlus related topics: Liver Diseases

Drug Information available for: Magnesium sulfate Magnesium gluconate Magnesium

U.S. FDA Resources

Further study details as provided by National Center for Research Resources (NCRR):

Estimated Enrollment:	25
Study Start Date:	October 2000

Detailed Description:

PROTOCOL OUTLINE:

Patients receive magnesium sulfate IV over 1 hour on day 3. Patients then receive oral magnesium gluconate supplementation daily. Treatment with magnesium sulfate repeats once at 3-6 months.

Eligibility

Ages Eligible for Study:	3 Years to 18 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Diagnosis of liver disease with chronic cholestasis Nonsyndromic intrahepatic cholestasis Alagille's syndrome Extrahepatic biliary atresia
Direct bilirubin greater than 2 mg/dL OR Bile acids greater than 20 micromoles/L
No hepatic decompensation defined as one or more of the following: Ascites Peripheral edema PT at least 4 seconds longer than control Albumin less than 3 g/dL

--Patient Characteristics--

Renal: No significant renal disease
Cardiovascular: No significant cardiovascular disease
Pulmonary: No significant pulmonary disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00007033

Locations

United States, Ohio
Children's Hospital Medical Center - Cincinnati
Cincinnati, Ohio, United States, 45229-3039

Sponsors and Collaborators

National Center for Research Resources (NCRR)

Children's Hospital Medical Center, Cincinnati

Investigators

Study Chair:

James Heubi

Children's Hospital Medical Center, Cincinnati

More Information

Publications:

Heubi JE, Wiechmann DA, Creutzinger V, Setchell KD, Squires R Jr, Couser R, Rhodes P. Tauroursodeoxycholic acid (TUDCA) in the prevention of total parenteral nutrition-associated liver disease. J Pediatr. 2002 Aug;141(2):237-42.

Study ID Numbers:	199/15488, CHMC-C-91-3-7
Study First Received:	December 6, 2000
Last Updated:	January 21, 2009
ClinicalTrials.gov Identifier:	NCT00007033 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Center for Research Resources (NCRR):

Alagille syndrome
biliary atresia
cholestasis
gastrointestinal disorders
rare disease

Additional relevant MeSH terms:

Liver Diseases
Molecular Mechanisms of Pharmacological Action
Cholestasis
Magnesium Sulfate
Physiological Effects of Drugs
Calcium Channel Blockers
Anesthetics
Reproductive Control Agents
Biliary Atresia
Membrane Transport Modulators
Cholestasis, Intrahepatic
Pathologic Processes
Tocolytic Agents
Sensory System Agents
Therapeutic Uses

Biliary Tract Diseases
Alagille Syndrome
Syndrome
Abnormalities, Multiple
Cardiovascular Diseases
Anti-Arrhythmia Agents
Analgesics
Congenital Abnormalities
Disease
Cardiovascular Abnormalities
Central Nervous System Depressants
Cardiovascular Agents
Pharmacologic Actions
Digestive System Abnormalities
Digestive System Diseases

ClinicalTrials.gov processed this record on November 27, 2009